High-throughput drug screening of fine-needle aspiration-derived cancer organoids

STAR Protoc. 2020 Dec 16;1(3):100212. doi: 10.1016/j.xpro.2020.100212. eCollection 2020 Dec 18.


Generation of fine-needle aspiration (FNA)-derived cancer organoids has allowed us to develop a number of downstream applications. In this protocol, we start with organoids cultured in a semi-solid format. We dissociate organoids into single cells and then plate in a 384-well format for high-throughput drug screening. While this method must be fine-tuned for each individual organoid culture, it offers a format well suited for rapidly screening medium-sized drug/compound libraries (500-5,000 molecules) and generating dose-response curves to measure relative efficacy. For complete details on the use and execution of this protocol, please refer to Lee et al. (2020) and Vilgelm et al. (2020).

Keywords: Cancer; Cell culture; Cell-based Assays; High Throughput Screening; Organoids.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biopsy, Fine-Needle / methods*
  • Cell Culture Techniques / methods
  • Drug Evaluation, Preclinical / methods*
  • Early Detection of Cancer / methods
  • High-Throughput Screening Assays / methods*
  • Humans
  • Neoplasms / metabolism
  • Organoids / cytology
  • Organoids / metabolism